UPDATE: Equities.com Publishes Video Interview about Immune Pharmaceuticals Financing

Los Angeles, Calif., July 29, 2015 (GLOBE NEWSWIRE) — Equities.com, an interactive online community for financial publication, today published a Video Interview with Dr. Daniel Teper, CEO of Immune Pharmaceuticals, Inc. (NASDAQ:IMNP).Immune Pharmaceuticals secured today funding of up to $21.5 Million from institutional investors, $12 Million in Equity Financing and up to $9.5 Million in Debt Financing. Company to Advance its Immuno-Dermatology and Inflammatory Bowel Disease Product CandidatesLead Compound Bertilimumab, First-in-Class Autoimmune Therapy, a Priority.

(see here: http://immunepharmaceuticals.com/).

Click the following link to watch the video interview on EQUITIES.COM

Please review important disclosures on our website at: EQUITIES.COM

About Immune Pharmaceuticals

Immune Pharmaceuticals Inc. applies a personalized approach to treating and, developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis as well as for bullous pemphigoid, an orphan auto-immune dermatological condition. Immune’s pipeline also includes NanomAbs®, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet™, a topical neuropathic pain drug candidate.

For more information, visit Immune’s website at www.immunepharmaceuticals.com

About Equities.com

Equities.com is an online financial news organization and social community for self-directed investors, public and private companies, market experts, and professional service providers across the global capital markets. The Equities.com Issuer Dashboard is an ideal platform to effectively manage corporate communication and investor awareness campaigns, engage with market intermediaries and financial advisors, and research industry peers. Registered members can leverage our market-leading commentary and content curation, as well as our proprietary research tools. Go tohttp://www.equities.com/community/register to become a member.

info@equities.com

310-822-5500

editor@equities.com

Retrieved from “http://globenewswire.com/news-release/2015/07/29/756177/10143805/en/UPDATE-Equities-com-Publishes-Video-Interview-about-Immune-Pharmaceuticals-Financing.html

About The Wall Street Analyzer 1608 Articles
The Wall Street Analyzer's staff of writers, analysts, publishers, producers, market researchers, and PR professionals aim to provide investors with the tools they need to make informed decisions on buying stock. Our staff is a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum.